Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...
Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...
11h
Ensuring Purity and Performance: The Rise of Top Pharmaceutical and Electrochemical Manufacturers
HANGZHOU CITY, ZHEJIANG, CHINA, January 19, 2026 /EINPresswire.com/ -- With the development of the pharmaceutical and ...
The cell and gene therapy industry will greatly benefit from access to robust, scalable, end-to-end solutions for the production and characterization of native and engineered exosome therapeutics.” — ...
BILLERICA, Mass.--(BUSINESS WIRE)--Nirrin Technologies, a company developing analytical systems to transform analysis for downstream bioprocessing operations, showcased three enabling at-line/in-line ...
Standards organization says R2v3 certification entails accurately portraying operations of facilities receiving components and materials. SERI says qualifications for a non-R2v3 downstream vendor are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results